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By comparing the results of energy calculation for ru-MSH and its semirigid analogues Ac- 
[C~~~,~S”]-CY-MSIJ~-WNHZ, Ac-[C~~~S’~]XY-MSH.+I~-NH~, and [Cys4-Cys1’]iu-MSH, a detailed 
description of two possible bioactive conformations for the ‘specific’ central site of (Y-MSI-& is proposed 
representing variants of chain-reversal structure. A possible xplanation of the rise in melanotropic activity 
of the latter two semirigid analogues i presented. 
cu-Melanotropin Energy calculation Conformation-function relationship 
Cyclic analog Melanotropic activity 
1. INTRODUCTION 2. METHODS AND RESULTS 
An important landmark in investigation of con- 
formation-function relationships for the a-melano- 
tropin molecule (cu-MSH, Ac-Seri-Tyr’-Ser3-Met4- 
Glu5-His6-Phe7-Arg8-Trp9-Gly1o-Lys11-Pro’2-Val’3- 
NH2) has been the synthesis and biological testing 
of semirigid cu-MSH analogues such as Ac- 
[C~~~-~S’~]-CY-MSH~_~O-NH~ (I), AC-[&~, Cys”]- 
a-MS&-is-NH2 (II) and [Cys”, C$.lo]~-MSH (III) 
described in [ 1,2]. The aim of this study was to 
determine the bioactive conformation of a specifi- 
cally active fragment of the molecule, namely 
His6-Phe’-Arg*-Trp’, which allegedly represents a 
@turn-like structure. It has been found that the 
above analogues exhibit melanotropic activity in 
vitro in the frog (Rana &iens) skin assays equal 
to 0.07, -lo4 and -104, respectively, as compared 
to c~-MSH activity. Furthermore, compounds II 
and III, but not I also showed a substantial pro- 
longation of action [2]. Apparently, the following 
stage of conformation-function studies with LY- 
MSH should, in our view, involve a comparison of 
the spatial structures of (Y-MSH and I-III ana- 
logues aimed at identification and detailed descrip- 
tion of bioactive conformations of the a-MSHa-9 
fragment. 
The sets of low-energy backbone structures of 
compounds I-III described here were obtained 
by means of similar energy calculations to the 
procedure applied to the a-MSH molecule in the 
study of [3]. An additional modification of the 
calculation technique was the use of ‘closing’ 
potentials for disulphide bond description (cf. [4]). 
The general outline of calculations implied step- 
wise elongation of the peptide chain by the fol- 
lowing steps Ac-[C~~~S’~]-(Y-MSI-L-~O-NH~ + 
I I AC-[Cys4, C~S’~]-CY-MSH~-~~-NH~ -* [Cys4, Cys*‘]- 
wMSH accompanied by optimization of side chain 
spatial arrangement and selection of low-energy 
(A (IQ lo-15 kcal/mol) backbone structures at each 
stage; thereby the intermediate results of calcula- 
tions reported in [3] were employed extensively. 
A detailed description of the calculation pro- 
cedure and the obtained sets of low-energy struc- 
tures for compounds I-III will be published else- 
where. Listed below (table 1) are only the sets of 
low-energy backbone conformations for com- 
pounds I (AU< 10 kcal/mol), II and III (AU < 12 
kcal/mol) in terms of local minima of potential 
maps of amino acid residues: B (p - -140”, 
G-140”), R (v,$-60”), L (~,,#1-,60”) and H 
(p - I40”,# - -80”) (internal rotation angle 
values are estimated according to [5]). 
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3. DISCUSSION 
As bioactive conformations of the wMSH+9 
fragment in this case may be apparently regarded 
as the backbone structures of this fragment listed 
in table 1 for all the compounds included in it (for 
the description of the ‘conventional’ procedure for 
bioactive conformation identification see e.g. [6]). 
Similar structures - conformations of RRBR and 
RRRB type - are treated in greater detail in table 2 
and are depicted in fig.1 for the Ac-[Cywy~‘~]- 
~-MSH~-WNH~ molecule. It should be pointed 
out in this connection that the backbone confor- 
mations of the N-terminal tripeptide appear in- 
essential for the general spatial organization of 
compound III and hence the list of low-energy 
molecular structures in table 1 comprises only 
variants of these conformations optimal with 
regard to the C-terminal decapeptide. 
Similarity (or difference) of both types of struc- 
tures with the bioactive conformation suggested 
for III in [l] can be easily deduced from fig. 1. 
Thus, hydrogen bonding between NHT,, and 
COm, postulated in [l] is absent in both cases, al- 
though NHGI” . * - COarg (fig. la) or NHT, * * * COelu 
(fig.lb) bonds are conceivable. Interaction of the 
lipophilic regions on the side chains of Lys and 
Trp, but not Phe is possible only for the structure 
in fig.lb, while attraction of the Glu and Lys side 
chains is feasible only for the structure in fig. la. It 
must be pointed out that close spatial arrangement 
of ionogenic functional groups Glu(-) . -. (+)Arg is 
observed in almost all the structures listed in table 
1, whereas in the cyclic compounds II and III only 
one type of structure permits the same arrange- 
ment of Giuf-) +. * (+)Lys. Hence, in most cases 
the Lys side chain rather acts as a spacer involved 
in direct interaction with receptors than as a factor 
of additional stabilization of the bioactive confor- 
mations of the central LY-MSH6_9 fragment. This 
restriction on conformational mobility of the Lys 
residue may be possibly ascribed to additional 
steric hindrance provided by the disulphide bridge 
or to the substitution in II and III of the ‘confor- 
mational hinge’ Gly” for a Cys residue. It is also 
noteworthy too that one of the hypothetical bio- 
active conformations proposed by us for the 
central cu-MSH fragment (RRRB for cu-MSHs-9) 
within cyclic compounds reproduces more ac- 
curately the steric organization of the linear 
mu-MSH (see table 2). Incidentally, in this particular 
structure the side chain of Lys is located far from 
the cx-MSH6_9 region (fig. lb). 
Table 1 
Low-energy backbone structures of cu-MSH [3] and semirigid analogues 
Compound Structural Structure Sequential number AU Distance (A) 
group 
1 2 3 4 5 6 7 8 9 10 11 12 13 
(kcal/mol) 
Cb,- C&,- 
CL,, Xv, 
CPMSH I 
II 
III 
IV 
V 
VI 
VII 
VIII 
1 BLRRB BRRB 
2 BRRBB BRRB 
3 BBBBB BRRB 
4 BBRBB BRRB 
5 BBRBB RBRB 
6 BLRRB BRRR 
7 BRRBB RRRB -.-- 
8 BRRRB BLRB 
9 BRRRB BLRB 
10 BRRRB BLRR 
11 BRRBL RBBB 
12 RLRBB RBBB 
13 BBRBL RRBR 
LBRB 0.0 3.3 8.8 
HBBB 4.4 3.3 10.9 
BBRB 6.7 4.4 3.8 
RBBB 7.0 3.4 12.4 
LBRB 5.0 3.8 3.5 
RBBB 5.0 3.4 8.5 
BBRB 5.4 3.1 4.4 
LBBB 4.6 5.3 2.9 
HBBB 10.9 5.5 3.0 
RBBB 8.0 5.5 3.4 
LBRB 9.3 4.0 3.5 
LBRB 9.8 4.1 3.5 
BBRB 11.2 3.7 3.6 
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Table 1 (Continued) 
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Compound Structural Structure Sequential number AU Distance (A) 
II 
III 
group 
I I 1 
2 
II 3 
4 
III 5 
IV 6 
V 7 
VI 8 
VII 9 
10 
VIII 11 
IX 12 
X 13 
XI 14 
I 1 
2 
3 
4 
5 
6 
7 
II 8 
III 9 
10 
IV 11 
12 
13 
14 
V 15 
16 
VI 17 
I 1 
II 2 
3 
III 4 
IV 5 
- 
12345 6 7 8 9 10 11 12 13 (kcal’mol) cd d au- Call- 
B B LLRB 
RL LLRB 
BB LLRR 
RL LLRR 
RB RRBB 
BB BRRR 
RB RRRR 
BB RRRB 
B B L L B B 
B L LLBB 
BB RRRL 
BR BRRB 
BR RRLR 
BR RBRB 
RL 
BB 
BB 
RL 
B B 
RL 
BB 
RB 
BB 
BB 
BB 
BB 
RL 
RL 
RB 
B B 
BR 
BBBRB RRBR BBRB 0.0 
BBBRB RRBB BBRB 5.9 
BBBRB RRBB BBBB 8.9 
BBBBB RRRB BBBB 7.6 
BBBBR RLRR B B B B 9.5 
LLRR 
LLRR 
LLRR 
LLRR 
LLRR 
LLRR 
LLRR 
RRBR 
RRRB 
RRRB 
LLRB 
LLRB 
LLRB 
LLRB 
RRBB 
RRBB 
RLRR 
BBRB 
BBRB 
BBBB 
BBBB 
BLBB 
BLBB 
BLRB 
BBRB 
BBBB 
BBRB 
BBBB 
BBRB 
BBRB 
BBBB 
0.0 
0.8 
1.0 
1.3 
4.5 
6.6 
8.6 
1.9 
7.0 
10.8 
9.0 
10.0 
10.6 
11.6 
BBBB 10.2 
BBBB 12.0 
BBBB 10.8 
0.0 4.5 
4.7 3.9 
2.6 4.8 
7.8 3.7 
3.7 8.0 
4.1 3.5 
4.4 3.2 
4.7 2.7 
7.9 3.8 
8.9 3.3 
8.0 4.3 
8.3 5.0 
9.5 4.8 
9.6 8.3 
3.6 
4.7 
4.5 
3.6 
4.8 
3.6 
4.6 
4.7 
4.0 
3.9 
4.6 
4.7 
3.7 
3.8 
3.4 
3.3 
9.0 
4.8 
3.5 
3.3 
4.0 
9.3 
9.9 
12.5 
12.6 
10.2 
16.0 
15.2 
17.4 
3.6 
18.1 
16.6 
20.5 
20.4 
12.1 
18.5 
17.6 
19.9 
13.2 
3.6 
17.4 
17.9 
18.1 
13.2 
The underlined structures are described in greater detail in table 2 
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Table 2 
Hypothetical bioactive conformations of Lu-melanotropin 
Residue Angle compound no. of structure in table 1 
Structure 1 (RRBR for wMSH6-9) Structure 2 (RRRB for rr-MSHa-9) 
cr-MSH I II III a-MSH I II III 
13 7 8 1 7 8 9 10 4 
Met 
(Cys) 
Glu 
His 
Phe 
Arg 
Trp 
GIY P -82 
(CYS) 6 76 
LYS P 
4J 
-143 
133 
Pro 
VaI 
s 
P -117 
rt 129 
-127 
141 
65 
133 
-104 
-28 
-37 
-44 
-123 
140 
-117 
-49 
-115 -115 
-44 -44 
-138 -138 
154 156 
-83 -82 
-36 -36 
-76 -76 
-39 -39 
-129 -129 
148 147 
-52 -53 
-54 -55 
-161 -161 
140 145 
-127 
140 
-40 
-130 
140 
-106 -121 -145 -145 -145 -14.5 
-45 110 162 165 165 165 
-139 -152 -122 -121 -122 -121 
156 144 118 117 116 117 
-84 -71 -71 -73 -74 -73 
-35 -22 -22 -21 -21 -21 
-75 -53 -70 -67 -67 -67 
-40 -35 -43 -42 -41 -42 
-129 -92 -96 -94 -93 -94 
148 -53 -78 -79 -80 -79 
-51 -154 -158 -161 -161 -161 
-55 144 139 140 133 140 
-161 -4s -145 -145 -154 -145 
146 103 141 I41 141 141 
-127 -135 -131 -138 -131 
139 136 122 130 122 
-41 
-130 
139 
-30 
-120 
137 
118 -36 118 
-142 -138 -142 
152 150 152 
Internal rotation angle values are expressed in degrees 
Reduced conformational mobility observed for should be additionally investigated which exhibits, 
the Lys residue in compounds II and III may be, as shown in [7], still greater prolongation of 
in principle, related to the dramatic increase in melanotropi~ effect. 
their biological activity in the case when the side Our calculation results agree fairly well with the 
chain of Lys interacts directly with the receptor. existence of a chain-reversal structure in ty- 
However, more important in this respect is ap- MSHs-9 postulated in [l] for the biologically 
parently the marked restriction of the set of pos- active U-MSH conformation and provide some 
sible backbone conformations for the ‘specific’ insight as to the possible structures of this region 
region ~MsH6-9 (11, 6 and 4 structures for com- (table 2). Experimental verification of biologically 
pounds I, II and III, respectively; see table 1). At active structures described for rw-MSH in table 2 
the same time, to analyse a possible relationship can be possibly obtained by the synthesis and 
between the prolonged action of compounds II and biological testing of compounds possessing still 
III and their conformational properties the spatial greater rigidity of the or-MSH6-9 region, e.g. as has 
structures of the [Nle4, D-Phe?]-tr-MSH analogue been performed for the tuftsin molecule [S]. 
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b) 
Fig.1. Stereo views of hypothetical bioactive conformations of (r-h&H (Ac-[C~~~S’~~-CU-MSH~_IS-NH~ cyclo- 
analogue). Hydrogen atoms except for those of the C-terminal amide have been omitted. Indicated in black are the 
cu-MSHa_9 fragment backbone and the atoms whose interato~c distances are given in table I. (a) Structure 8, (b) 
structure 9 from table 1. 
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